SG11201407841YA - Novel therapeutic treatments with anti-her2 antibodies having a low fucosylation - Google Patents
Novel therapeutic treatments with anti-her2 antibodies having a low fucosylationInfo
- Publication number
- SG11201407841YA SG11201407841YA SG11201407841YA SG11201407841YA SG11201407841YA SG 11201407841Y A SG11201407841Y A SG 11201407841YA SG 11201407841Y A SG11201407841Y A SG 11201407841YA SG 11201407841Y A SG11201407841Y A SG 11201407841YA SG 11201407841Y A SG11201407841Y A SG 11201407841YA
- Authority
- SG
- Singapore
- Prior art keywords
- therapeutic treatments
- novel therapeutic
- her2 antibodies
- low fucosylation
- fucosylation
- Prior art date
Links
- 230000033581 fucosylation Effects 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Radiology & Medical Imaging (AREA)
- Mycology (AREA)
- Pathology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261673216P | 2012-07-18 | 2012-07-18 | |
| US201261673201P | 2012-07-18 | 2012-07-18 | |
| US201261673229P | 2012-07-18 | 2012-07-18 | |
| EP12197768 | 2012-12-18 | ||
| PCT/EP2013/065189 WO2014013019A1 (en) | 2012-07-18 | 2013-07-18 | Novel therapeutic treatments with anti-her2 antibodies having a low fucosylation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407841YA true SG11201407841YA (en) | 2015-02-27 |
Family
ID=49948317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201407841YA SG11201407841YA (en) | 2012-07-18 | 2013-07-18 | Novel therapeutic treatments with anti-her2 antibodies having a low fucosylation |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20150166664A1 (enExample) |
| EP (1) | EP2874658A1 (enExample) |
| JP (1) | JP2015528802A (enExample) |
| KR (1) | KR20150036710A (enExample) |
| CN (1) | CN104394887A (enExample) |
| AU (1) | AU2013291964B2 (enExample) |
| BR (1) | BR112014032169A2 (enExample) |
| CA (1) | CA2875486A1 (enExample) |
| EA (1) | EA201590237A1 (enExample) |
| IL (1) | IL236714A0 (enExample) |
| MA (1) | MA37961A1 (enExample) |
| MX (1) | MX2015000730A (enExample) |
| NZ (1) | NZ701974A (enExample) |
| SG (1) | SG11201407841YA (enExample) |
| WO (1) | WO2014013019A1 (enExample) |
| ZA (1) | ZA201408938B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU92659B1 (en) * | 2015-02-23 | 2016-08-24 | Glycotope Gmbh | Glycooptimized antibody drug conjugates |
| JP2020512382A (ja) * | 2017-03-29 | 2020-04-23 | グリコトープ ゲーエムベーハー | Ｐｄ−ｌ１抗体およびｔａ−ｍｕｃ１抗体 |
| US12103978B2 (en) * | 2018-06-15 | 2024-10-01 | Shanghai Miracogen Inc. | Methods and materials for treating cancer |
| CA3112043A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| CN113999313A (zh) * | 2020-07-28 | 2022-02-01 | 百奥泰生物制药股份有限公司 | 抗her2抗体及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL220113B1 (pl) | 1999-01-15 | 2015-08-31 | Genentech Inc | Wariant macierzystego polipeptydu zawierającego region Fc, polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania receptora Fc gamma (FcγR), polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania noworodkowego receptora Fc (FcRn), kompozycja, wyizolowany kwas nukleinowy, wektor, komórka gospodarza, sposób otrzymywania wariantu polipeptydu, zastosowanie wariantu polipeptydu i sposób otrzymywania wariantu regionu Fc |
| EP2278003B2 (en) | 1999-04-09 | 2020-08-05 | Kyowa Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| MXPA03000105A (es) | 2000-06-28 | 2004-09-13 | Glycofi Inc | Metodo para producir glicoproteinas modificadas. |
| JP2005532253A (ja) | 2001-10-25 | 2005-10-27 | ジェネンテック・インコーポレーテッド | 糖タンパク質組成物 |
| JPWO2003084569A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物含有医薬 |
| ATE475708T1 (de) * | 2003-01-22 | 2010-08-15 | Glycart Biotechnology Ag | Fusionskonstrukte und deren verwendung zur produktion von antikörpern mit erhöhter fc rezeptor bindungsaffinität und effektorfunktion |
| FR2858235B1 (fr) | 2003-07-31 | 2006-02-17 | Lab Francais Du Fractionnement | Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs |
| JPWO2005053742A1 (ja) * | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
| WO2005086875A2 (en) * | 2004-03-11 | 2005-09-22 | City Of Hope | A humanized anti-cea t84.66 antibody and uses thereof |
| DOP2006000029A (es) * | 2005-02-07 | 2006-08-15 | Genentech Inc | Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas) |
| CN103436574B (zh) | 2006-09-10 | 2016-08-10 | 葛莱高托普有限公司 | 骨髓白血病来源的细胞在抗体表达中的用途 |
| CN102666874B (zh) * | 2009-10-07 | 2016-06-01 | 宏观基因有限公司 | 由于岩藻糖基化程度的改变而表现出改善的效应子功能的含Fc区的多肽及其使用方法 |
| US20120258496A1 (en) * | 2010-09-27 | 2012-10-11 | Boehringer Ingelheim International Gmbh | Production of low fucose antibodies in h4-ii-e rat cells |
-
2013
- 2013-07-18 BR BR112014032169A patent/BR112014032169A2/pt not_active IP Right Cessation
- 2013-07-18 JP JP2015522098A patent/JP2015528802A/ja active Pending
- 2013-07-18 NZ NZ701974A patent/NZ701974A/en not_active IP Right Cessation
- 2013-07-18 AU AU2013291964A patent/AU2013291964B2/en not_active Expired - Fee Related
- 2013-07-18 CN CN201380034959.0A patent/CN104394887A/zh active Pending
- 2013-07-18 KR KR20157004250A patent/KR20150036710A/ko not_active Withdrawn
- 2013-07-18 MX MX2015000730A patent/MX2015000730A/es unknown
- 2013-07-18 WO PCT/EP2013/065189 patent/WO2014013019A1/en not_active Ceased
- 2013-07-18 MA MA37961A patent/MA37961A1/fr unknown
- 2013-07-18 EA EA201590237A patent/EA201590237A1/ru unknown
- 2013-07-18 US US14/412,797 patent/US20150166664A1/en not_active Abandoned
- 2013-07-18 EP EP13739973.9A patent/EP2874658A1/en not_active Withdrawn
- 2013-07-18 CA CA2875486A patent/CA2875486A1/en not_active Abandoned
- 2013-07-18 SG SG11201407841YA patent/SG11201407841YA/en unknown
-
2014
- 2014-12-05 ZA ZA2014/08938A patent/ZA201408938B/en unknown
-
2015
- 2015-01-14 IL IL236714A patent/IL236714A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2875486A1 (en) | 2014-01-23 |
| MX2015000730A (es) | 2015-08-06 |
| IL236714A0 (en) | 2015-02-26 |
| EA201590237A1 (ru) | 2015-05-29 |
| MA37961A1 (fr) | 2016-06-30 |
| CN104394887A (zh) | 2015-03-04 |
| NZ701974A (en) | 2018-03-23 |
| ZA201408938B (en) | 2016-09-28 |
| EP2874658A1 (en) | 2015-05-27 |
| AU2013291964B2 (en) | 2017-12-14 |
| AU2013291964A1 (en) | 2015-02-05 |
| WO2014013019A1 (en) | 2014-01-23 |
| BR112014032169A2 (pt) | 2017-08-01 |
| JP2015528802A (ja) | 2015-10-01 |
| US20150166664A1 (en) | 2015-06-18 |
| KR20150036710A (ko) | 2015-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL271697A (en) | Antibodies against CXCR3 | |
| IL229254A0 (en) | Therapeutic antibodies | |
| ZA201507246B (en) | Anti-cancer treatments with anti-egfr antibodies having a low fucosylation | |
| IL239339A0 (en) | Therapeutic 47cd antibodies | |
| PT2707030T (pt) | Tratamentos de cancro | |
| GB201103955D0 (en) | Antibodies | |
| GB201112056D0 (en) | Antibodies | |
| ZA201305801B (en) | Heart valve | |
| IL230719A0 (en) | highly galactosylated antibodies | |
| HUE051320T2 (hu) | Humán anti-TAU antitestek | |
| PL2773338T3 (pl) | Poprawa rozpoznawania | |
| IL235994A0 (en) | Humanized anti-trka antibodies with amino acid substitutions | |
| PL2609894T3 (pl) | Zastawka serca | |
| EP2697575A4 (en) | TOROIDAL HELICOSTAT | |
| ZA201408938B (en) | Novel therapeutic treatments with anti-her2 antibodies having a low fucosylation | |
| PL2522433T3 (pl) | Korpus wielodyszowy z oświetleniem | |
| HRP20150166T8 (hr) | Montažni pomiäśni prst | |
| EP2714074A4 (en) | ANTIBODIES AGAINST EMR1 | |
| GB201114901D0 (en) | Vascular treatments | |
| GB201114582D0 (en) | Run around | |
| SG11201502303UA (en) | Multiple zone integrated intelligent well completion | |
| PL2785739T3 (pl) | Poprawa wyniku trabekulektomii | |
| GB201102913D0 (en) | Novel therapeutic | |
| ZA201308992B (en) | Therapeutic antibodies | |
| GB201120096D0 (en) | Novel therapy |